Mirum Shares Rise 3.3% After Livmarli Meets Phase 3 Primary Endpoint
Mirum Pharmaceuticals said Livmarli (maralixibat) met the primary endpoint in a trial treating cholestatic pruritus in certain patients with liver diseases. Shares rose 3.3% to $61.05 in premarket trading Monday.
Mirum Pharmaceuticals shares climbed after Livmarli, also known as maralixibat, met the primary endpoint in a recent trial evaluating treatment of cholestatic pruritus in certain patients with liver diseases. 05 in premarket trading on Monday. At Friday…